have mpn disparities been addressed by institutions?
Published 1 year ago • 12 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
3:33
are there any mpn disparities in subtypes and genetics?
-
5:13
understanding mpn treatment options | what’s available for mf, pv, and et?
-
3:24
expert perspective: hopeful mpn research and development
-
3:49
how are mpn treatments changing for low-risk vs high-risk patients?
-
1:52
mpn treatment tools and advancement
-
31:59
moderate-impact exercises for mpn patients
-
3:21
living with an mpn and being your own best advocate
-
1:00:46
ask an mpn expert: tracking and living with mpns
-
2:41
dr. idoroenyi amanam: why is it important for you to empower mpn patients?
-
33:24
which mpn treatment is right for you? what you need to know
-
33:45
what patients should know about developing mpn treatments and research
-
1:33
mpn patient q&a: how did you cope with a second mpn diagnosis?
-
2:11
resources for accessing mpn clinical trials
-
4:06
understanding and managing common mpn symptoms and side effects
-
3:16
how should you participate in mpn care and treatment decisions?
-
26:51
mpn patient q&a: how did you avoid obstacles to receiving the best myeloproliferative neoplasm care
-
2:19
mpn patient q&a: what questions should i ask if i suspect i have an mpn
-
4:03
understanding mpn treatment goals and shared decision-making
-
29:26
how clinical trials advance mpn treatment and research
-
1:57
should mpn patients and their families continue telemedicine?
-
2:09
what can mpn patients expect when starting a new treatment?
-
3:39
expert perspective | disease modification in polycythemia vera